MedPacto is an innovative drug discovery and development company based in South Korea that develops therapeutics targeting cancer and autoimmune diseases. Our expertise lies in utilizing genome-based methods to identify novel targets and function identification through pre-clinical studies and global clinical development

There is urgent need for new treatments that can overcome the limitations of existing anticancer drugs and MedPacto develops pipelines according to the trends’ needs.